Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

MSD, known as Merck & Co Inc in the United States and Canada, has been in Singapore for 30 years, employs over 1,800 people, ...

Merck & Co., Inc. (NYSE:MRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Merck & Co., Inc. (NYSE:MRK) has ...

In the trial, the combination of Padcev with Merck & Co.'s Keytruda showed a clinically meaningful and statistically significant improvement in event-free survival and overall survival when used ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...